{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:08:46Z","timestamp":1789564126568,"version":"build-2803163510"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jvascsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Vascular Surgery"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.jvs.2017.07.130","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T05:58:54Z","timestamp":1509688734000},"page":"800-808.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention"],"prefix":"10.1016","volume":"67","author":[{"given":"Thomas C.F.","family":"Bodewes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy D.","family":"Darling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.X.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Deery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie E.","family":"Shean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray A.","family":"Mittleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans L.","family":"Moll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc L.","family":"Schermerhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jvs.2017.07.130_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","article-title":"Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004","volume":"124","author":"Pande","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.07.130_bib2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.112.108787","article-title":"Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains","volume":"126","author":"Subherwal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.07.130_bib3","doi-asserted-by":"crossref","first-page":"e000697","DOI":"10.1161\/JAHA.113.000697","article-title":"Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease","volume":"3","author":"Armstrong","year":"2014","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jvs.2017.07.130_bib4","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.jvs.2013.03.050","article-title":"Optimal medical therapy predicts amputation-free survival in chronic critical limb ischemia","volume":"58","author":"Chung","year":"2013","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jvs.2017.07.130_bib5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/VHRM.S15484","article-title":"ACE up the sleeve - are vascular patients medically optimized?","volume":"7","author":"Coveney","year":"2011","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jvs.2017.07.130_bib6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.jacc.2005.09.074","article-title":"Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease","volume":"47","author":"Feringa","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2017.07.130_bib7","first-page":"e791","article-title":"2016 AHA\/ACC Guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.07.130_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib9","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib10","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jvs.2017.07.130_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ehj.2003.10.033","article-title":"Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease","volume":"25","author":"\u00d6stergren","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jvs.2017.07.130_bib12","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1177\/1060028013501803","article-title":"Angiotensin-converting enzyme inhibitors for intermittent claudication associated with peripheral arterial disease","volume":"47","author":"Hunter","year":"2013","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvs.2017.07.130_bib13","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1002\/bjs.9198","article-title":"Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication","volume":"100","author":"Shahin","year":"2013","journal-title":"Br J Surg"},{"key":"10.1016\/j.jvs.2017.07.130_bib14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2013.09.037","article-title":"Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication","volume":"231","author":"Shahin","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jvs.2017.07.130_bib15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia","volume":"20","author":"Armstrong","year":"2015","journal-title":"Vasc Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib16","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.07.130_bib17","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/pgmj.77.914.765","article-title":"A\u00a0survey of the dose of ACE inhibitors prescribed by general physicians for patients with heart failure","volume":"77","author":"McMullan","year":"2001","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.jvs.2017.07.130_bib18","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jacc.2016.05.011","volume":"68","author":"Yancy","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jvs.2017.07.130_bib19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jvs.2017.07.130_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1345\/aph.1C402","article-title":"High-versus low-dose ACE inhibitor therapy in chronic heart failure","volume":"38","author":"Roffman","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jvs.2017.07.130_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1053\/j.semvascsurg.2010.06.001","article-title":"Understanding objective performance goals for critical limb ischemia trials","volume":"23","author":"Conte","year":"2010","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.jvs.2017.07.130_bib22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/aje\/kwq439","article-title":"Doubly robust estimation of causal effects","volume":"173","author":"Funk","year":"2011","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jvs.2017.07.130_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1751-0473-3-17","article-title":"Purposeful selection of variables in logistic regression","volume":"3","author":"Bursac","year":"2008","journal-title":"Source Code Biol Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/VHRM.S3096","article-title":"Peripheral artery disease: potential role of ACE-inhibitor therapy","volume":"4","author":"Coppola","year":"2008","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.jvs.2017.07.130_bib25","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.ejvs.2004.08.003","article-title":"Manipulation of the renin angiotensin system in peripheral arterial disease","volume":"28","author":"Hobbs","year":"2004","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"10.1016\/j.jvs.2017.07.130_bib26","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1191\/1358863x03vm502oa","article-title":"The potential role of angiotensin-converting enzyme inhibition in peripheral arterial disease","volume":"8","author":"Hirsch","year":"2003","journal-title":"Vasc Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib27","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/archinternmed.2012.2514","article-title":"Improved outcomes in heart failure treated with high-dose ACE inhibitors and ARBs: a population-based study","volume":"172","author":"Egiziano","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib28","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jvs.2017.07.130_bib29","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/jamainternmed.2013.12700","article-title":"Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia","volume":"174","author":"Hsu","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jvs.2017.07.130_bib30","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jvs.2017.07.130_bib31","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/hc4101.096153","article-title":"Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association","volume":"104","author":"Schoolwerth","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jvs.2017.07.130_bib32","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1097\/HJH.0b013e328306ebe2","article-title":"Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis","volume":"26","author":"Reboldi","year":"2008","journal-title":"J\u00a0Hypertens"}],"container-title":["Journal of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521417320797?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0741521417320797?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:19:27Z","timestamp":1760041167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0741521417320797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0741521417320797"],"URL":"https:\/\/doi.org\/10.1016\/j.jvs.2017.07.130","relation":{},"ISSN":["0741-5214"],"issn-type":[{"value":"0741-5214","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention","name":"articletitle","label":"Article Title"},{"value":"Journal of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jvs.2017.07.130","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.","name":"copyright","label":"Copyright"}]}}